ROS1 and non-small cell lung carcinoma: In a study of 54 patients with ALK- or ROS1-positive NSCLC with or without brain metastases, loratinib treatment resulted in durable clinical responses with a 50% overall response rate, including intracranial responses, in ALK- and ROS1-positive NSCLC patients, many of whom had CNS metastases.